Cameroon

in page functions
[French]
Cameroon
Total population (2018) 25,111,643
Birth cohort (2018) 873,521
Surviving Infants (surviving to 1 year per year, 2018) 817,142
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 57/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 88/1000
World Bank Index, IDA (2015) 3.14
Gross Nation Income (per capita US$, 2015) 1,320
No. of districts/territories (2017) 189

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Cameroon

Type of support

Approvals

2001-2023 (US$)
(23 May 2019)

Commitments

2001-2023 (US$)
(23 May 2019)

Disbursements

2000-2019 (US$)
(23 May 2019)

% Disbursed

(23 May 2019)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $219,978,456 $239,602,956 $211,958,688
Cash Support (CASHSUPP) $203,000 $228,000 $203,000 100%
Civil Society Organisation support (CSO) $56,199 N/A
Cold Chain Equipment Optimisation Platform (CCEOP) $2,918,260 $2,918,260 $1,007,229 35%
Health system strengthening (HSS 1) $6,857,288 $6,857,288 $6,857,288 100%
Health system strengthening (HSS 2) $5,600,000 $23,520,000 $1,007,140 18%
HPV (NVS) $2,036,000 $3,698,000
HPV Demo (NVS) $492,308 $492,308 $493,787 100%
Immunisation services support (ISS) $7,983,620 $7,983,620 $7,983,620 100%
Injection Safety Devices (NVS) $942,030 $959,530 $811,497 86%
Injection safety support (INS) $992,844 $992,844 $992,844 100%
IPV (NVS) $3,955,995 $3,955,995 $3,498,667 88%
Measles-Rubella (NVS) $6,504,938 $6,504,938 $6,504,938 100%
Meningitis A - campaign (NVS) $4,324,774 $4,324,774 $4,324,774 100%
Meningitis A - operational costs (OPC) $2,508,980 $2,508,980 $2,508,980 100%
MR - Operational costs (OPC) $5,828,500 $5,828,500 $5,828,500 100%
MR 1st and 2nd dose (NVS) $615,000 $615,000 $647,330 105%
MR 2nd dose (NVS) N/A
MR-Follow-up campaign (NVS) $2,249,000 $2,249,000
MR-Follow-up campaign op.costs (OPC) $1,801,485 $1,801,485
Penta (NVS) $42,969,908 $42,969,908 $41,246,662 96%
Pneumo (NVS) $83,233,216 $83,233,216 $93,263,242 112%
Product Switch Grant (PSG) $259,500 $259,500
Rotavirus (NVS) $16,249,935 $16,249,935 $14,557,604 90%
Tetra DTP-HepB (NVS) $9,000,675 $9,000,675 $9,000,675 100%
Vaccine Introduction Grant (VIG) $4,459,117 $4,459,117 $2,755,500 62%
Yellow Fever (NVS) $7,992,083 $7,992,083 $8,409,212 105%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Cameroon DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2017)

Grade of confidence


N/A
DTP3 - Official country estimates (2017) 86%
M:F sex ratio at birth (2018) 1.03
Household survey: DTP3 coverage for male (2010) 68.10%
Household survey: DTP3 coverage for female (2010) 68.60%
Household survey: Last DTP3 survey (2010) 68%
% districts achieving > 80% DTP3 coverage (2017) 71%
% districts achieving < 50% DTP3 coverage (2017) 2%
MCV WHO/UNICEF estimates (2017) 77%

Breakdown of support

Non-vaccine support Vaccine support
14% 86%
$29,200,300 $182,758,388

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Cameroon

11 June 2019

EPI LAMP Yaounde

New management training for immunisation leaders kicks-off at the University of Yaounde

National teams from six Gavi-supported countries will attend the first forum of the nine-month programme.

19 September 2016

Stockpiling

On the frontline: Gavi's support to fragile states

With more than half of Gavi-supported countries officially listed as fragile states, Gavi is increasingly working on several fronts to ensure vaccines still reach people living on the frontlines of humanitarian crises.

23 May 2016

Cameroon cholera campaign

World Humanitarian Summit - Gavi's Fragility and Immunisation Policy

Gavi to review its response to humanitarian emergencies and fragile settings in 2016.

Disclaimer: the boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of Gavi, the Vaccine Alliance concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

close icon

modal window here